New monitoring methods tested for haemophilia b treatment
NCT ID NCT04590950
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study involved 15 people with severe haemophilia B who were already taking eftrenonacog-alfa, a clotting factor medicine. Researchers compared different lab tests to see which ones best measure factor IX activity in real-life conditions. The goal was to improve monitoring of how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eftrenonacog-alfa (recombinant factor IX Fc)
- What this could lead to
- If successful, this study could improve how doctors monitor treatment effectiveness for severe haemophilia B patients.
- What could go wrong
- This is a small, observational study with only 15 participants, so results may not apply broadly. It does not test a new treatment or aim to change outcomes directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE HAEMOPHILIA B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service d'hématologie biologique - Hôpital Cochin
Paris, 75014, France